NasdaqGM:RLAYBiotechs
Relay Therapeutics (RLAY): Reassessing Valuation After Renewed Institutional Buying and Late-Stage Trial Progress
Commodore Capital’s decision to lift its stake in Relay Therapeutics (RLAY) after adding nearly 3.7 million shares is catching investors attention, especially as the company tightens spending and extends its cash runway.
See our latest analysis for Relay Therapeutics.
Those moves seem to be feeding into sentiment, with a 90 day share price return of around 87 percent and a 1 year total shareholder return above 70 percent, suggesting that momentum is rebuilding after a tough multi year...